A Systematic Review of Economic Studies Evaluating Ophthalmic Drugs: An Analysis of the Health-state Utilities

被引:1
作者
Ribeiro, Ines [1 ,2 ]
Batel Marques, Francisco [1 ,3 ]
Mendes, Diogo [1 ]
Alves, Carlos [1 ,3 ]
机构
[1] CHAD Ctr Hlth Technol Assessment & Drug Res, AIBILI Assoc Innovat & Biomed Res Light & Image, Coimbra, Portugal
[2] Univ Coimbra, Fac Pharm, Coimbra, Portugal
[3] Univ Coimbra, Fac Pharm, Lab Social Pharm & Publ Hlth, Coimbra, Portugal
关键词
Systematic review; cost-utility; ophthalmology; utilities; COST-EFFECTIVENESS ANALYSIS; VERTEPORFIN PHOTODYNAMIC THERAPY; DIABETIC MACULAR EDEMA; VALUE-BASED MEDICINE; POLLEN INDUCED RHINOCONJUNCTIVITIS; RETINAL VEIN OCCLUSION; QUALITY-OF-LIFE; DRY EYE DISEASE; NONINFECTIOUS INTERMEDIATE; INTRAVITREAL AFLIBERCEPT;
D O I
10.1080/09286586.2020.1792938
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose To characterize the techniques used to derive health-state utilities (HSU) in the cost-utility studies (CUS) of ophthalmic drugs. Methods A systematic review was conducted in Pubmed/Embase until October 2019. CUS evaluating ophthalmic drugs were included. Therapeutic area, technique to derive HSU and sources of HSU were extracted. It was assessed if the HSU and the other parameters of CUS were collected from the same population. The techniques to derive HSU used in the CUS were compared to the techniques recommended by the country-specific economic evaluation guidelines. Results Seventy CUS were included. Forty-three (61.4%) used direct techniques to derive HSU, 19 (27.1%) used indirect, 1 (1.4%) used direct and indirect and the remaining (n = 7; 10.0%) used other or unknown techniques. Twelve (17.1%) CUS collected the HSU and the other parameters from the same population: nine (12.9%) retrieved utility data from experimental studies, two (2.9%) from observational and one (1.4%) from other sources. Forty-eight (68.6%) CUS collected the HSU and the other parameters from different populations: eight (11.4%) retrieved utility data from experimental studies, 33 (47.1%) from observational, one (1.4%) from both experimental and observational and six (8.6%) from other sources. It was not possible to identify the population from whom data were obtained in 10 (14.3%) CUS. Eleven (15.7%) CUS followed the recommendations of guidelines, 21 (30.0%) did not follow and for 38 (54.3%), it was not possible to assess. Conclusion Choosing different techniques to derive HSU may result in different results, which can preclude the comparison between cost-utility studies.
引用
收藏
页码:325 / 338
页数:14
相关论文
共 50 条
  • [1] A systematic review of the methodological quality of economic studies evaluating ophthalmic drugs
    Ribeiro, Ines Souto
    Batel Marques, Francisco Jorge
    Alves, Dalila Gil
    Costa Alves, Carlos Miguel
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2019, 19 (04) : 421 - 430
  • [2] An analysis of the effectiveness outcomes of economic studies evaluating ophthalmic drugs: a systematic review
    Ribeiro, Ines
    Marques, Francisco Batel
    Alves, Dalila
    Alves, Carlos
    ACTA OPHTHALMOLOGICA, 2020, 98 (03) : 237 - 243
  • [3] Health-state utilities in liver disease: A systematic review
    McLernon, David J.
    Dillon, John
    Donnan, Peter T.
    MEDICAL DECISION MAKING, 2008, 28 (04) : 582 - 592
  • [4] Characteristics of health-state utilities used in cost-effectiveness analyses: a systematic review of published studies in Asia
    Yang, Zhihao
    Zeng, Xueyun
    Huang, Weidong
    Chai, Qingqing
    Zhao, Angela
    Chuang, Ling-Hsiang
    Wu, Bin
    Luo, Nan
    HEALTH AND QUALITY OF LIFE OUTCOMES, 2023, 21 (01)
  • [5] Characteristics of health-state utilities used in cost-effectiveness analyses: a systematic review of published studies in Asia
    Zhihao Yang
    Xueyun Zeng
    Weidong Huang
    Qingqing Chai
    Angela Zhao
    Ling-Hsiang Chuang
    Bin Wu
    Nan Luo
    Health and Quality of Life Outcomes, 21
  • [6] Health state utilities for economic evaluation of bariatric surgery: A comprehensive systematic review and meta-analysis
    Xia, Qing
    Campbell, Julie A.
    Ahmad, Hasnat
    Si, Lei
    de Graaff, Barbara
    Otahal, Petr
    Palmer, Andrew J.
    OBESITY REVIEWS, 2020, 21 (08)
  • [7] Comprehensive Health-State Utilities in Contemporary Patients With Cirrhosis
    Foster, Chelsey
    Baki, Jad
    Nikirk, Samantha
    Williams, Sydni
    Parikh, Neehar D.
    Tapper, Elliot B.
    HEPATOLOGY COMMUNICATIONS, 2020, 4 (06) : 852 - 858
  • [8] Mapping Studies to Estimate Health-State Utilities From Nonpreference-Based Outcome Measures: A Systematic Review on How Repeated Measurements are Taken Into Account
    Goncalves, Ana Sofia Oliveira
    Werdin, Sophia
    Kurth, Tobias
    Panteli, Dimitra
    VALUE IN HEALTH, 2023, 26 (04) : 589 - 597
  • [9] Health State Utilities for Sickle Cell Disease: A Catalog Prepared From a Systematic Review
    Jiao, Boshen
    Basu, Anirban
    Ramsey, Scott
    Roth, Joshua
    Bender, M. A.
    Quach, Dalyna
    Devine, Beth
    VALUE IN HEALTH, 2022, 25 (02) : 276 - 287
  • [10] Health State Utilities of Patients with Heart Failure: A Systematic Literature Review
    Di Tanna, Gian Luca
    Urbich, Michael
    Wirtz, Heidi S.
    Potrata, Barbara
    Heisen, Marieke
    Bennison, Craig
    Brazier, John
    Globe, Gary
    PHARMACOECONOMICS, 2021, 39 (02) : 211 - 229